Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins-Reference-Cited by-同舟云学术

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins

Published:2018-09-25 Issue:13 Volume:138 Page:1304-1316
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Ray Kausik K.¹,Stoekenbroek Robert M.²,Kallend David³,Leiter Lawrence A.⁴,Landmesser Ulf⁵,Wright R. Scott⁶,Wijngaard Peter³,Kastelein John J.P.²

Affiliation:

1. Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, UK (K.K.R.).

2. Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, the Netherlands (R.M.S., J.J.P.K.).

3. The Medicines Company, Parsippany, NJ (D.K., P.W.).

4. Division of Endocrinology and Metabolism, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, University of Toronto, Canada (L.A.L.).

5. Department of Cardiology, Charité–Universitätsmedizin Berlin, Berlin Institute of Health and German Center for Cardiovascular Research, Partner Site Berlin, Germany (U.L.).

6. Department of Cardiology, Mayo Clinic, Rochester, MN (R.S.W.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference39 articles.

1. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials

2. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

3. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration [published online ahead of print August 14, 2017].;Ference BA;Eur Heart J

4. Paper presented at: American College of Cardiology Annual Meeting Orlando FL March 10–12 2018 Paper presented at: American College of Cardiology Annual Meeting PG Steg ODYSSEY OUTCOMES Investigators and Committees ODYSSEY Outcomes: CV outcomes with alirocumab after ACS.

5. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inclisiran siRNA technology in the management of dyslipidemia: A narrative review of clinical trials;Current Problems in Cardiology;2024-04

2. Effective prevention of atherosclerosis by non-viral delivery of CRISPR/Cas9;Nano Today;2024-02

3. LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics;Annual Review of Pharmacology and Toxicology;2024-01-23

4. PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke;Frontiers in Pharmacology;2024-01-11

5. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside;Signal Transduction and Targeted Therapy;2024-01-08